제조과정에서 단백질 약물의 생물학적 활성의 보존은 약물의 성공적인 전달에 있어 여전히 중요한 과제이다. 이중에멀션 유기용매 증발법을 사용하여 나노입자를 제조하였고, 입자의 형태, 크기, 함입률 그리고 방출속도와 방출되는 효소의 활성을 살펴보았다. 입자의 크기는 고분자인 락타이드 글리콜라이드 공중합체의 농도가 증가할수록 커졌으며, 유화제의 농도에는 큰 차이가 없었으나, 4% PVA의 사용에서 가장 좁은 입자분포를 얻을 수 있었다. 최적의 조건에서 72.6%의 단백질 함입률과 $198.3{\pm}13.8 nm$ 크기의 나노입자를 얻었다. 입자로부터 효소의 방출은 첫 방출시기에 매우 빠르게 일어났으며 12일 내에 83%가 방출되었다. 이에 따른 방출되는 효소의 활성은 6일째까지 증가되었다.
제조과정에서 단백질 약물의 생물학적 활성의 보존은 약물의 성공적인 전달에 있어 여전히 중요한 과제이다. 이중에멀션 유기용매 증발법을 사용하여 나노입자를 제조하였고, 입자의 형태, 크기, 함입률 그리고 방출속도와 방출되는 효소의 활성을 살펴보았다. 입자의 크기는 고분자인 락타이드 글리콜라이드 공중합체의 농도가 증가할수록 커졌으며, 유화제의 농도에는 큰 차이가 없었으나, 4% PVA의 사용에서 가장 좁은 입자분포를 얻을 수 있었다. 최적의 조건에서 72.6%의 단백질 함입률과 $198.3{\pm}13.8 nm$ 크기의 나노입자를 얻었다. 입자로부터 효소의 방출은 첫 방출시기에 매우 빠르게 일어났으며 12일 내에 83%가 방출되었다. 이에 따른 방출되는 효소의 활성은 6일째까지 증가되었다.
The preservation of biological activity of protein drugs in formulation is still a major challenge for successful drug delivery. Lipase was encapsulated in poly (D,L-lactide- co-glycolide) PLGA nano-particles using a w/o/w solvent evaporation technique. The lipase-containing PLGA/poly (vinyl alcohol...
The preservation of biological activity of protein drugs in formulation is still a major challenge for successful drug delivery. Lipase was encapsulated in poly (D,L-lactide- co-glycolide) PLGA nano-particles using a w/o/w solvent evaporation technique. The lipase-containing PLGA/poly (vinyl alcohol) (PVA) nanoparticles were characterized with regard to morphology, size, size distribution, lipase-loading efficiency, in vitro lipase release, and stability of lipase activity. The size of nanoparticles increased as polymer concentration was increased. The size of particles was not significantly affected by the PVA concentration; on the other hand, the particle size distribution was the narrowest when 4% of PVA was used. In optimum conditions, we possessed nanoparticles that characterized 72.5% of encapsulation efficiency, $198.3{\pm}13.8 nm$ size diameter. During the initial burst phase, the in vitro release rate was very fast, reaching 83% within 12 days. Until days 6, enzyme activity increased as the amount of lipase released was increased.
The preservation of biological activity of protein drugs in formulation is still a major challenge for successful drug delivery. Lipase was encapsulated in poly (D,L-lactide- co-glycolide) PLGA nano-particles using a w/o/w solvent evaporation technique. The lipase-containing PLGA/poly (vinyl alcohol) (PVA) nanoparticles were characterized with regard to morphology, size, size distribution, lipase-loading efficiency, in vitro lipase release, and stability of lipase activity. The size of nanoparticles increased as polymer concentration was increased. The size of particles was not significantly affected by the PVA concentration; on the other hand, the particle size distribution was the narrowest when 4% of PVA was used. In optimum conditions, we possessed nanoparticles that characterized 72.5% of encapsulation efficiency, $198.3{\pm}13.8 nm$ size diameter. During the initial burst phase, the in vitro release rate was very fast, reaching 83% within 12 days. Until days 6, enzyme activity increased as the amount of lipase released was increased.
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
제안 방법
parameters. In order to optimize the lipase encapsulation in this method, concentrations of PLGA and PVA were examined. Figure 2 shows that the encapsulation efficiency of lipase increased with increasing polymer con— entration, and also showed that the encapsulation efficiency of lipase decreased with increasing PVA concentration.
In this study, we used the lipase enzyme to examine the release rate and stability of the activity in the PLGA/ poly (vinyl alcohol) (PVA) nanoparticles.
이론/모형
Particle size and polydispersity were determined by the light scattering method(DLS-8000, Otsuka Electronics, Japan). For measurement, 0.
The lipase-loaded nanoparticles were encapsuled using the w/o/w double emulsion solvent evaporation method. The PLGA(3%)/PVA(4%) composite nanoparticles possessed a spherical shape and narrower size distribution.
참고문헌 (24)
E. K. Janatuinen, P. H. Pikkarainen, T. A. Kemppainen, V. M. Kosma, R. M. Jarvinen, M. I. Uusitupa, and R. J. Julkunen, N. Engl. J. Med., 333, 1033 (1995)
T. Hickey, D. Kreutzer, D. J. Burgess, and F. Moussy, J. Biomed. Mater. Res., 61, 80 (2002)
A. M. Cohen and E. Rosenmann, Horm. Metab. Res., 22, 511 (1990)
D. F. Emerich, M. A.Tracy, K. L. Ward, M. Figueiredo, R. Qian , C. Henschel, and R. T. Bartus, Cell. Transplant., 8, 47 (1999)
L. Branon Papper, Int. J. Pharm., 116, 1 (1995)
M. S. Shive and J. M. Anderson, Adv. Drug. Deliv. Rev., 28, 5 (1997)
T. Gomer, R. Gref, D. Michenot, F. Sommer, M. N. Tran, and E. Dellacherie, J. Control. Release, 57, 259 (1999)
K. E. Uhrich, S. M. Cannizzaro, R. S. Langer, and K. M. Shakesheff, Chem. Rev., 99, 3181 (1999)
R. A. Jain, Biamaterials, 21, 2475 (2000)
S. J. Lee, Y. J. Park, S. N. Park, Y. M. Lee, Y. J. Seol, Y. Ku, and C. P. Chung, J. Biomed. Mater. Res., 55, 295 (2001)
※ AI-Helper는 부적절한 답변을 할 수 있습니다.